Latest Tax Incentives News

Assetora Limited has dramatically reduced its net liabilities and strengthened its balance sheet through strategic capital raises and debt conversions, while unveiling a comprehensive rebrand and leadership expansion to drive its next growth phase.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy by executing three CAR-T term sheets and completing technical due diligence, while implementing cost-cutting measures and seeking new capital amid a tough financing environment.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

Mighty Kingdom Limited reports a positive operating cash inflow and significant cost reductions in Q3 FY25, alongside leadership changes and a $3.35 million capital raise underway to fuel growth.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

AdNeo Limited reports a positive operating cash flow for Q3 FY25, driven by a 60% surge in customer receipts and cost savings exceeding targets. Strategic SaaS contracts and platform upgrades underpin its growth trajectory.

Cardiex reports strong early sales momentum for its CONNEQT Pulse device with approximately 3,000 units sold or contracted since its mid-January launch, supported by innovative app features and operational efficiencies. Despite regulatory delays in the US pharma sector and tariff challenges, the company is positioned for scalable growth and category leadership in preventative cardiovascular care.

Cardiex Limited reported a $2.06 million cash outflow for Q3 2025 but is driving cost savings and new revenue streams while planning a capital raise to reach positive cash flow.

Anatara Lifesciences reports mixed results from its Phase II GaRP-IBS trial, missing the primary efficacy target but showing significant improvements in anxiety and patient-reported relief, while advancing its anti-obesity pre-clinical program.

FBR Limited wraps up its US Demonstration Program, secures $6.3 million in capital, and appoints Mark Pivac as CEO amid a 70% cost reduction drive. Strategic collaborations with Samsung Heavy Industries and Liebherr signal broader automation ambitions.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.